Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2567-2574

  Singh, Rana P ^a,b   Deep, Gagan ^a   Blouin, Marie José ^c   Pollak, Michael N ^c   Agarwal, Rajesh ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; SILIBININ; SOMATOMEDIN BINDING PROTEIN 3; SURVIVIN; VASCULOTROPIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DENSITY; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MICROVASCULATURE; MITOSIS INHIBITION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIET; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SILYMARIN; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36949029439     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm218     Document Type: Article

References (35)

1. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
2. Kelloff,G.J. et al. (1999) Chemoprevention of prostate cancer: concepts and strategies. Eur. Urol., 35, 342-350.
3. Bosland,M.C. et al. (2002) Chemoprevention strategy for prostate cancer. Eur. J. Cancer Chemoprev., 11, S18-S27.
4. Surh, Y.J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 3, 768-780.
5. Koivisto,P. et al. (1998) Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol., 152, 1-9.
6. FeldmanB.J. et al. (2001) The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1, 34-45.
7. Agarwal,R. et al. (2000) Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol., 60, 1051-1059.
8. Singh,R.P. et al. (2004) Prostate cancer prevention by silibinin. Curr. Cancer Drug Targets, 4, 1-11.
9. Wellington,K. et al. (2001) Silymarin: A review of its clinical properties in the management of hepatic disorders. BioDrugs, 15 465-489.
10. Zi,X. et al. (1999) Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc. Natl Acad. Sci. USA, 96, 7490-7495.
11. Dhanalakshmi,S. et al. (2002) Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene, 21, 1759-1767.
12. Singh,R.P. et al. (2002) Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice, and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res., 62, 3063-3069.
13. Agarwal,C. et al. (2003) Silibinin up-regulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene, 22 8271-8282.
14. Zi,X. et al. (2000) Silibinin up-regulates insulin-like growth factor binding protein-3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res., 60, 5617-5620.
15. Deep,G. et al. (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: A comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene, 25, 1053-1069.
16. Singh,R.P. et al. (2003) Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol. Biomarkers Prev., 12, 933-939.
17. Singh,R.P. et al. (2006) Effect of silibinin on the growth and progression of primary lung tumors in mice. J. Natl Cancer Inst., 98, 846-855.
18. Gurumurthy,S. et al. (2001) Regulation of apoptosis in prostate cancer. Cancer Melastasis Rev., 20, 225-243.
19. Naumov,G.N. et al. (2006) Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle, 5 1779-1787.
20. Singh,R.P. et al. (2003) Tumor angiogenesis: A potential target in cancer control by phytochemicals. Curr Cancer Drug Targets, 3 205-217.
21. Rubinfeld,H. et al. (2005) The ERK cascade: A prototype of MAPK signaling. Mol. Biotechnol., 31, 151-174.
22. Bodo,J. et al. (2007) Isothiocyanate E-4IB induces MAPK activation, delayed cell cycle transition and apoptosis. Cell Prolif. 40, 316-326.
23. Mallikarjuna,G. et al. (2004) Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res., 64, 6349-6356.
24. Chokkalingam,A.P. et al. (2001) Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev., 10, 421-427.
25. Pollak,M.N. et al. (2004) Insulin-like growth factors and neoplasia. Nat. Rev. Cancer, 4, 505-518.
26. DiGiovanni,J. et al. (2000) Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl Acad. Sci. USA, 97, 3455-3460.
27. Rajah,R. et al. (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem., 272, 12181-12188.
28. Singh,R.P. et al. (2006) Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, 13, 751-778.
29. Singh,R.P. et al. (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and down-regulation of survivin, Akt and NF-kappaB: Implications for angioprevention and antiangiogenic therapy. Oncogene, 24, 1188-1202.
30. Xiong,Y. et al. (1993) P21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
31. Singh,R.P. et al. (2002) Phytochemicals as cell cycle modulators: a less toxic approach in halting human cancer. Cell Cycle, 1 156-161.
32. Toyoshima,H. et al. (1994) P27, a novel inhibitor of G1 cyclin-CDK protein kinase activity, is related to p21. Cell, 78, 67-74.
33. Cheng,L. et al. (2000) The cell cycle inhibitors p21/waf1 and Kip1/p27 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin. Cancer Res., 6, 1896-1899.
34. Yang,R.M. et al. (1998) Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159, 941-945.
35. Flaig,T.W. et al. (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs, 25, 139-146.